Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel F Hayes

Showing results (231-240 of 336) with videos related to

Pageof 34
Sort By:
Clinical Chemistry|October 5, 2012
Design of tumor biomarker-monitoring trials: a proposal by the European Group on Tumor MarkersGyörgy Sölétormos, Michael J Duffy, Daniel F Hayes, et al.
Plos One|November 15, 2021
PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancerElizabeth P Darga, Emily M Dolce, Fang Fang, et al.
Biosensors & Bioelectronics|February 14, 2006
Point-of-care biosensor systems for cancer diagnostics/prognosticsSteven A Soper, Kathlynn Brown, Andrew Ellington, et al.
Journal of the National Cancer Institute|December 7, 2006
p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapyPeggy L Porter, William E Barlow, I-Tien Yeh, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|January 17, 2023
Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226)Mattias Bergqvist, Adrian Nordmark, Amy Williams, et al.
JCO Precision Oncology|November 16, 2023
Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination DeficiencyShane R Stecklein, William Barlow, Lajos Pusztai, et al.
JCO Precision Oncology|January 12, 2023
Tumor-Derived Extracellular Vesicles as Complementary Prognostic Factors to Circulating Tumor Cells in Metastatic Breast CancerAfroditi Nanou, Jieling Miao, Frank A W Coumans, et al.
The Oncologist|March 25, 2016
Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast CancerKunal C Kadakia, Claire F Snyder, Kelley M Kidwell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2013
Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumorsAnne F Schott, Melissa D Landis, Gabriela Dontu, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 3, 2009
AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonistDaniel R Rhodes, Bushra Ateeq, Qi Cao, et al.
Pageof 34

Showing results (231-240 of 336) with videos related to

Sort By:
Pageof 34
Clinical Chemistry|October 5, 2012
Design of tumor biomarker-monitoring trials: a proposal by the European Group on Tumor MarkersGyörgy Sölétormos, Michael J Duffy, Daniel F Hayes, et al.
Plos One|November 15, 2021
PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancerElizabeth P Darga, Emily M Dolce, Fang Fang, et al.
Biosensors & Bioelectronics|February 14, 2006
Point-of-care biosensor systems for cancer diagnostics/prognosticsSteven A Soper, Kathlynn Brown, Andrew Ellington, et al.
Journal of the National Cancer Institute|December 7, 2006
p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapyPeggy L Porter, William E Barlow, I-Tien Yeh, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|January 17, 2023
Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226)Mattias Bergqvist, Adrian Nordmark, Amy Williams, et al.
JCO Precision Oncology|November 16, 2023
Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination DeficiencyShane R Stecklein, William Barlow, Lajos Pusztai, et al.
JCO Precision Oncology|January 12, 2023
Tumor-Derived Extracellular Vesicles as Complementary Prognostic Factors to Circulating Tumor Cells in Metastatic Breast CancerAfroditi Nanou, Jieling Miao, Frank A W Coumans, et al.
The Oncologist|March 25, 2016
Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast CancerKunal C Kadakia, Claire F Snyder, Kelley M Kidwell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2013
Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumorsAnne F Schott, Melissa D Landis, Gabriela Dontu, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 3, 2009
AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonistDaniel R Rhodes, Bushra Ateeq, Qi Cao, et al.
Pageof 34